Correction to: N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial (Annals of Oncology (2010) 21(8) (1729–1730), (S0923753419353116), (10.1093/annonc/mdp328))

W. W. Tan, D. W. Hillman, M. Salim, D. W. Northfelt, D. M. Anderson, P. J. Stella, R. Niedringhaus, A. M. Bernath, S. S. Gamini, F. Palmieri, E. A. Perez

Research output: Contribution to journalComment/debatepeer-review

1 Scopus citations

Abstract

Ann Oncol 2010; 21: 493–497 (doi: 10.1093/annonc/mdp328) The following funding statement was missing from the original manuscript: ‘Supported by NIH grant U10CA025224 to the North Central Cancer Treatment Program.’ This has now been amended in the online version.

Original languageEnglish (US)
Pages (from-to)2150
Number of pages1
JournalAnnals of Oncology
Volume29
Issue number10
DOIs
StatePublished - Oct 2018

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Correction to: N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial (Annals of Oncology (2010) 21(8) (1729–1730), (S0923753419353116), (10.1093/annonc/mdp328))'. Together they form a unique fingerprint.

Cite this